Arizona State Retirement System Has $98,000 Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Arizona State Retirement System raised its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 22.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,458 shares of the company’s stock after acquiring an additional 5,543 shares during the quarter. Arizona State Retirement System’s holdings in Allogene Therapeutics were worth $98,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC boosted its position in Allogene Therapeutics by 0.9% in the third quarter. FMR LLC now owns 25,143,931 shares of the company’s stock valued at $79,706,000 after buying an additional 225,976 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Allogene Therapeutics by 41.1% in the third quarter. Vanguard Group Inc. now owns 10,587,804 shares of the company’s stock valued at $33,563,000 after acquiring an additional 3,086,311 shares during the last quarter. Rafferty Asset Management LLC boosted its holdings in shares of Allogene Therapeutics by 2.2% in the 3rd quarter. Rafferty Asset Management LLC now owns 904,403 shares of the company’s stock worth $2,867,000 after acquiring an additional 19,832 shares in the last quarter. Barclays PLC grew its position in Allogene Therapeutics by 17.6% during the 3rd quarter. Barclays PLC now owns 786,793 shares of the company’s stock worth $2,495,000 after acquiring an additional 117,596 shares during the last quarter. Finally, Caxton Associates LP increased its holdings in Allogene Therapeutics by 590.0% during the 3rd quarter. Caxton Associates LP now owns 480,104 shares of the company’s stock valued at $1,522,000 after purchasing an additional 410,520 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ALLO shares. JPMorgan Chase & Co. reduced their price objective on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 27th. Guggenheim lowered shares of Allogene Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, January 5th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research note on Tuesday, March 19th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 15th. Finally, JMP Securities reissued a “market perform” rating on shares of Allogene Therapeutics in a research note on Friday, January 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.94.

Allogene Therapeutics Stock Performance

ALLO opened at $3.40 on Tuesday. The company has a fifty day moving average price of $4.46 and a two-hundred day moving average price of $3.55. The firm has a market capitalization of $574.91 million, a PE ratio of -1.63 and a beta of 0.81. Allogene Therapeutics, Inc. has a 52 week low of $2.23 and a 52 week high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.04. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. Equities analysts forecast that Allogene Therapeutics, Inc. will post -1.69 EPS for the current year.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).